About Us

Global Hemp Group Inc. (CSE: GHG / FRANKFURT: GHG0 ) is currently focused on two business segments:

BioPharma Division

GHG has expanded its scope of business into natural biologic therapeutics by acquiring the exclusive licensing of patents and IP of Apollon Formularies plc (a UK-based international pharmaceutical company developing cancer treatments from natural biologics, including cannabinoids, functional mushrooms, and combinations of these compounds, which to date have shown successful independent, third-party results in pre-clinical testing), and executing a Letter of Intent with B-Organic R&D Corp. for their Bioactive Lipid Agents (“BLA”) technology, a patented innovative matrix which is able to increase the solubility and bioavailability of numerous “poorly soluble pharma ingredients” including cannabinoids.

Industrial Hemp Division 

The development and promotion of hemp-based products that are sustainable, environmentally friendly, and have a positive impact on society. Products that include, but not limited to, the carbon negative use of hemp-based construction materials and carbon neutral bio-energy sources. To further support and innovate, GHG’s R&D Division is pursuing the development of Intellectual Property that can be patented for implementation at its projects and beyond. The Division is led by Prof. Víctor M. Castaño, Ph.D. whose career has focused in the areas of applied science and technology.